Expertise and ambition put ‘unique’ Tubulis at forefront of ADC movement

German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing.

This is the latest recognition of the company’s strength in the antibody drug conjugate (ADC) field, following on from previous funding rounds and a licensing deal with pharma major Bristol Myers Squibb (NYSE: BMY).

It is also evidence of Tubulis’ good timing, since ADCs are in vogue with investors and big pharma at the moment as a rapidly emerging class of therapeutic agents that combine the target specificity of a monoclonal antibody with the lethality of cytotoxic cellular poison.